Brean Capital Initiates Coverage On Osiris Therapeutics By: Benzinga via Benzinga December 29, 2014 at 17:05 PM EST Brean Capital initiated coverage on Osiris Therapeutics, Inc. (NASDAQ: OSIR) Monday with a Buy rating and $19 price ... Read More >> Related Stocks: Osiris Therapeutics